Raji/Luc & Human CD19 Knockout Stable Cell Line

1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
3. Comprehensive application data to support assay development and validation
4. Full tracible record, stringent quality control and validated cell passage stability
5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
6. Global commercial license assistance whenever regulatory filing is required

Description

The Raji/Luc & Human CD19 Knockout Stable Cell Line was generated from Raji cells through targeted knockout of human CD19 (Gene ID: 930) and engineered to express the firefly luciferase reporter. The expression level of human CD19 was confirmed by flow cytometry. The luciferase activity was confirmed by the detection of luminescence signal. Mutated sequences of human CD19 produced by non-homologous end joining (NHEJ) were confirmed through genomic sequencing.

Application

• Useful for cell-based CD19 target-specific analysis

• Used as target cells for luminescence-based cytotoxicity evaluation

Growth Properties

Suspension

Selection Marker

Puromycin (2 μg/mL)

Complete Growth Medium

RPMI-1640 + 10% FBS

Freeze Medium

Serum-free cell cryopreservation medium

Quantity

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

Storage

Frozen in liquid nitrogen.

Mycoplasma Testing

Negative

Sterility Testing

Negative

Instructions for Use

See data sheet for detailed culturing and assay protocol.

ACRO Quality Management System

1. QMS(ISO, GMP)
2. Quality Advantages
3. Quality Control Process